



VERITAS PHARMA INC. ANNOUNCES APPOINTMENT OF NEW INDEPENDENT DIRECTOR; DR. DONALD R. CARLOW

April 19, 2016, Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy, today announced that Dr. Donald R. Carlow joined its board of directors as an independent director, effective immediately. With this addition, Veritas has increased the size of its board to 5 members, 3 of whom are independent.

Dr. Donald R. Carlow is a Health Care Consultant, past CEO of the Canadian Association of Provincial Cancer Agencies (CAPCA) past President and CEO of the Ontario Cancer Institute/Princess, Margaret Hospital and the past President and CEO of the British Columbia Cancer Agency. He was a member of the governing council of the Canadian Strategy for Cancer Control, has consulted widely on provincial Cancer control systems throughout Canada and was recently a member of the board of the Vancouver Island Health Authority.

"We are pleased to welcome Dr. Carlow to the Board of Directors", commented Veritas President and CEO Dr. Lui Franciosi. "Dr. Carlow has extensive experience in leadership roles with many of Canada's largest cancer organizations as well as being a chief medical officer for some of Canada's largest hospitals and was instrumental in the creation of the Canadian Association of Provincial Cancer Agencies. Dr. Carlow will provide Veritas' Board with strengthened insight as it pertains to the strategy, organizational systems, governance, medical and clinical management experience." Dr. Carlow stated, "It is my pleasure to join the Board of Veritas and I look forward to assisting in the realization of new clinical applications for cannabinoids. Finding answers to the questions regarding cannabis and cancer will require a concerted effort by patients, scientists and clinicians as well as the industry which will lead to better cancer care."

Dr. Donald R. Carlow

Dr. Carlow is past President and CEO of the British Columbia Cancer Agency (BCCA) (January 1994 until October 2000). At BCCA Dr. Carlow led substantial redesign and redevelopment of the agency. This included new cancer centers, as well as laying the groundwork for the new BC Cancer Research Center. During his term at BCCA, the Agency received a provincial award for quality planning. Under his leadership Canada's first high throughput gene sequencing center was established at the BCCA.

Dr. Carlow is the past CEO of the Canadian Association of Provincial Cancer Agencies - an organization devoted to coordinating the activities of cancer agencies across Canada. He also served as a member of the governing council of the Canadian Strategy for Cancer Control from 2000 to 2003. From September 1988 to December 1993, Dr Carlow was President and CEO of the Ontario Cancer Institute at Princess Margaret Hospital, which is Canada's largest cancer hospital located in Toronto, Ontario. At the Ontario Cancer Institute, Dr Carlow led the process of rebuilding the OCI/PMH in a new location. Dr. Carlow also led the organization through a major quality transformation and received an award from the Ontario College of Physicians and Surgeons for leadership in medical quality. While in Ontario, Dr. Carlow chaired the Ontario CQI Network as well as the Senior Leaders Forum for Quality.



From 1985 to 1988 Dr. Carlow was the Senior VP Medical for the Winnipeg Health Sciences Center and Associate Dean Clinical on The University of Manitoba - Faculty of Medicine. Prior to this, Dr. Carlow was Vice President Medical for the Victoria General Hospital for 11 years and prior to that practiced family medicine in Victoria BC. Dr. Carlowe holds a MD from the University of British Columbia – Faculty of Medicine where he graduated with honors in 1960. In 2001 he received the Queens Golden Jubilee Medal for service to community and country. He led the creation of the Canadian Association of Provincial Cancer Agencies, and served as its first Executive Director for three years.

Dr. Carlow is currently the president of Lynross Consulting a firm engaged in various health care consulting activities. Through this company Dr. Carlow has led consulting teams in reviewing cancer control programs in various provinces, including New Brunswick--where he assisted in redesign of the cancer control system. Dr. Carlow has also led similar activities in Manitoba and Newfoundland. He is also the medical consultant to the DAP and recently on behalf of the Emergency Health Services Commission undertook a comprehensive review of EMA medical oversight in BC. Dr. Carlow also led the external review of the Manitoba Diagnostic Accreditation Program (MANQAP). Dr. Carlow was/is a member of the board of the Vancouver Island Health Authority, where he chaired the board's health quality committee for four years. He proposed the establishment of the BC Council on Quality and Safety. Dr. Carlow was also a judge for the 3M National Health Care Quality Awards for four years during the 90's.

About VERITAS Pharma Inc.

Veritas Pharma Inc. is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a 'lean and mean' approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas's scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share.

On behalf of the Board of Directors
Veritas Pharma Inc.

"Dr. Lui Franciosi"
Dr. Lui Franciosi
Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact

Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785



Email: ir@veritaspharmainc.com

Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.